India, April 17 -- image credit- shutterstock

Zynext VenturesUSALLC, the venture capital arm of Ahmedabad-based Zydus Lifesciences, has announced its investment in Feldan Therapeutics, aCanada-based early clinical-stage pharmaceutical company pioneering the development of treatments based on intracellular delivery of therapeutics.

Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities. The company's lead candidate, FLD-103, is administered directly into basal cell carcinoma (BCC) lesions, where the Shuttle peptide facilitates the delivery of a Hedgehog inhibitor to its target within BCC cells. This innovative approach aims to provide...